NCT07389187
Safety and Preliminary Efficacy Evaluation of LC-K76 Plus Anti-PD-1 Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
StatusNot Yet Recruiting
PhaseEarly Phase 1
SponsorShanghai Changzheng Hospital
Primary completion (estimated)
At risk: Primary completion moved at least 11 months later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Primary completion pushed from Dec 2026 to Dec 2027
- Start date: Feb 2026 to Jun 2027
- Eligibility criteria shortened, about 5 words
- Site contact updated
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Incidence of Adverse Events (AEs)
Timeframe: From baseline to primary completion, which may take up to 24 to 48 weeks
Secondary (4)
PSA Response Rate
Disease control rate (DCR)
Radiographic Progression-Free Survival (rPFS)
Time to First Skeletal-Related Event (SRE)
Arms and interventions
LC-K76 + Tislelizumab + ADTExperimental
Participants receive oral LC-K76 combined with intravenous Anti-PD-1 monoclonal antibody (Tislelizumab) and standard androgen deprivation therapy (ADT). Treatment continues for 24 weeks.
Dietary supplements: LC-K76
Drugs: Tislelizumab, Standard Androgen Deprivation Therapy (ADT)
Sites
1 site in 1 country
- Changzheng hospitalShanghai, Shanghai Municipality, China